Article Text

Download PDFPDF
Prevalence of serrated polyposis syndrome in an FIT-based colorectal cancer screening cohort in Italy
  1. Dora Colussi1,
  2. Rocco Maurizio Zagari1,
  3. Beatrice Morini1,
  4. Margherita Fabbri1,
  5. Amedeo Montale1,
  6. Cesare Hassan2,
  7. Carlo Senore3,
  8. Franco Bazzoli1,
  9. Luigi Ricciardiello1,4
  1. 1 Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
  2. 2 Endoscopy Unit, Nuovo Regina Margherita Hospital, Rome, Italy
  3. 3 Città della Salute e della Scienza University Hospital, SCDO Epidemiology, Screening, Cancer Registry, CPO, Turin, Italy
  4. 4 Center for the Research on Hereditary Cancers, University of Bologna, Bologna, Italy
  1. Correspondence to Dr Luigi Ricciardiello, Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, PAD.11, Bologna 40138, Italy; luigi.ricciardiello{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the Editor

We read with interest the recent data reported by IJspeert et al,1 Biswas et al 2 and Moreira et al 3 whom evaluated the prevalence of serrated polyposis syndrome (SPS), a disease characterised by the development of multiple serrated polyps throughout the colon with an increased risk to develop colorectal cancer (CRC),4 inside CRC screening programmes. A guaiac faecal occult blood test cohort from the UK showed a frequency of SPS ranging from 0.03% to 0.66%.1 ,2 Other cohorts based on primary colonoscopy showed a prevalence of SPS between 0.1% and 0.4%.1 The only published data on SPS frequency within faecal immunochemical test (FIT) programmes are from Spain and ranged from 0.34% to 0.8%.1 ,3 Since FIT has widely become the method of choice for …

View Full Text


  • Contributors DC reviewed patient charts, acquired the data and drafted the manuscript; RMZ performed statistical analysis and interpreted the data; BM, MF and AM reviewed patient charts and acquired the data; CH, CS and FB assisted in the interpretation of data and revision of the manuscript; LR was responsible for the study, study concept, reviewed and interpreted the data and drafted the manuscript.

  • Funding LR is supported by the Italian Association for Cancer Research (AIRC) Investigator Grant No. 14281 and the European Community's Seventh Framework Programme FP7/2007–2013 under grant agreement 311876, Pathway-27.

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.